Skip to Main Content

Two clinical trials of an off-the-shelf CAR-T cancer therapy from Cellectis (CLLS) have been placed on clinical hold following the death of a patient caused by a severe toxic reaction to the treatment.

Cellectis’ stock price is down 30 percent to $22.79 in early Tuesday trading. The biotech company, with operations in Paris and New York, announced the FDA clinical hold on Sunday night.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!